Drug resistance interpretation: PR HIVDB 9.5.1 (2023-11-05)

PI Major Mutations:

None None

PLAccessory Mutations: PR Other Mutations:

L101 am ... + 113V am ... + K14R am ... + K20R am ... + K2

Protease Inhibitors

atazanavir/r (ATV/r) Susceptible darunavir/r (DRV/r) Susceptible lopinavir/r (LPV/r) Susceptible

PR comments

Other

- . L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.
- K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:

E44D em K103N

NNRTI Mutations: RT Other Mutations:

abacavir (ABC)

zidovudine (AZT)

lamivudine (3TC)

tenofovir (TDF)

emtricitabine (FTC)

A371V • I375V • A376V • T377Q • S379C • I382V

Nucleoside Reverse Transcriptase Inhibitors	
---	--

Susceptible Susceptible Susceptible Susceptible Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR) Susceptible efavirenz (EFV) High-Level Resistance etravirine (ETR) Susceptible nevirapine (NVP) High-Level Resistance

Susceptible

rilpivirine (RPV)

RT comments

E44D is a relatively non-polymorphic accessory mutation; E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs.

NNRTI

NRTI

K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.

Other

. V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

brug residence mutation scores or remire.					
Rule	DOR ÷	EFV ≑	ETR ÷		

Download CSV NVP ÷ RPV 60 60 0